公开(公告)号：EP2112220A3

公开(公告)日：2010-01-06

申请号：EP09157028.3

申请日：1997-07-15

申请人： The Government of the United States of America, as represented by The Department of Health and Human Services

发明人： Murphy, Brian ,  Collins, Peter ,  Whitehead, Stephen ,  Bukreyev, Alexander ,  Juhasz, Katalin ,  Teng, Michael

IPC分类号： C12N7/04 ,  C12N7/01 ,  A61K39/155 ,  C12N15/45 ,  C12N7/00

CPC分类号： C07K14/005 ,  A61K39/00 ,  C12N7/00 ,  C12N2760/18522 ,  C12N2760/18561

摘要： Attenuated respiratory syncytial virus (RSV) and vaccine compositions thereof are produced by introducing specific mutations associated with attenuating phenotypes into wild-type or RSV which is incompletely attenuated by cold-passage or introduction of mutations which produce virus having a temperature sensitive (ts) or cold adapted (ca) phenotype. Alternatively, recombinant RSV and vaccine compositions thereof incorporate attenuating and other mutations specifying desired structural and or phenotypic characteristics in an infectious RSV. Recombinant RSV incorporate desired mutations specified by insertion, deletion, substitution or rearrangement of a selected nucleotide sequence, gene, or gene segment in an infectious RSV clone. The immune system of an individual is stimulated to induce protection against natural RSV infection, or multivalently against infection by RSV and another pathogen, such as PlV, by administration of attenuated, biologically derived or recombinant RSV.

公开(公告)号：EP2112220A2

公开(公告)日：2009-10-28

申请号：EP09157028.3

申请日：1997-07-15

申请人： The Government of the United States of America, as represented by The Department of Health and Human Services

发明人： Murphy, Brian ,  Collins, Peter ,  Whitehead, Stephen ,  Bukreyev, Alexander ,  Juhasz, Katalin ,  Teng, Michael

IPC分类号： C12N7/04 ,  C12N7/01 ,  A61K39/155 ,  C12N15/45 ,  C12N7/00

CPC分类号： C07K14/005 ,  A61K39/00 ,  C12N7/00 ,  C12N2760/18522 ,  C12N2760/18561

摘要： Attenuated respiratory syncytial virus (RSV) and vaccine compositions thereof are produced by introducing specific mutations associated with attenuating phenotypes into wild-type or RSV which is incompletely attenuated by cold-passage or introduction of mutations which produce virus having a temperature sensitive (ts) or cold adapted (ca) phenotype. Alternatively, recombinant RSV and vaccine compositions thereof incorporate attenuating and other mutations specifying desired structural and or phenotypic characteristics in an infectious RSV. Recombinant RSV incorporate desired mutations specified by insertion, deletion, substitution or rearrangement of a selected nucleotide sequence, gene, or gene segment in an infectious RSV clone. The immune system of an individual is stimulated to induce protection against natural RSV infection, or multivalently against infection by RSV and another pathogen, such as PlV, by administration of attenuated, biologically derived or recombinant RSV.

摘要翻译： 减毒的呼吸道合胞病毒（RSV）及其疫苗组合物通过将与将减毒表型相关的特异突变引入野生型或RSV，通过冷通道或引入产生具有温度敏感性（ts）或 冷适应（ca）表型。 或者，重组RSV及其疫苗组合物结合了在感染性RSV中指定所需结构和/或表型特征的减毒和其它突变。 重组RSV包含通过在感染性RSV克隆中选择的核苷酸序列，基因或基因片段的插入，缺失，取代或重排而指定的所需突变。 通过施用减毒的，生物衍生的或重组的RSV，刺激个体的免疫系统以诱导针对天然RSV感染的保护，或多次抵抗RSV和另一种病原体（例如PlV）的感染。